---

---

tags : Disease   

save search

---

First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients
Published: 2024-04-24 (Crawled : 11:00) - globenewswire.com
FWBI | $3.12 7.22% 0.68% 220 |

Manufacturing

| Email alert Add to watchlist
first disease biopharma for

---

GeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease Dataset
Published: 2024-04-23 (Crawled : 12:30) - globenewswire.com
WGS | $12.0 15.5% 13.74% 240K |

Professional, Scientific, and T...

| 22.82% | O: 4.71% H: 22.87% C: 17.3%
partnership rare disease health

---

Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
Published: 2024-04-23 (Crawled : 12:00) - globenewswire.com
HOWL | $6.44 5.75% 4.99% 15 |

Professional, Scientific, and T...

| 7.33% | O: 2.17% H: 5.06% C: 5.06%
il-10 first disease preclinical for meeting therapeutics potential therapy

---

Quest Diagnostics Adds p-tau217 Blood Biomarker Testing to Suite of Services Designed to Assess Risk and Help Aid Diagnosis of Alzheimer's Disease
Published: 2024-04-22 (Crawled : 14:00) - biospace.com/
DGX | News | $136.7 5.08% 0.0% 1.8M |

Health Services

| 6.43% | O: 0.33% H: 0.0% C: 0.0%
disease services biomarker blood risk alzheimer's diagnostics

---

NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
Published: 2024-04-22 (Crawled : 13:00) - biospace.com/
NRSN | News | $1.36 0.74% -6.77% 79K |

| -4.23% | O: -1.41% H: 2.86% C: -3.57%
precision disease ongoing alzheimer's collaboration trial

---

Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease
Published: 2024-04-22 (Crawled : 12:00) - globenewswire.com
CGTX | News | $2.0 7.53% 7.92% 140K |

| 8.7% | O: -2.17% H: 7.78% C: 3.33%
disease alzheimer’s treat for therapeutics platform

---

U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Published: 2024-04-18 (Crawled : 23:00) - biospace.com/
TAK | News | $13.38 0.15% 1.94% 1.7M |

Health Technology

| 1.48% | O: 0.0% H: 0.0% C: 0.0%
entyvio fda disease active for therapy

---

Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
CERE | $41.99 -0.26% -0.26% 1.4M |

Finance

| 1.02% | O: 0.78% H: 0.0% C: 0.0%
disease positive for topline parkinson’s trial therapeutics results living

---

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
CMMB | $0.67 1.53% 0.02% 7.2K |

Manufacturing

| 2.92% | O: -3.38% H: 0.0% C: 0.0%
ccl24 disease association publication sclerosis

---

Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
SAGE | $12.95 0.47% 0.39% 820K |

Health Technology

| -15.08% | O: -15.02% H: 3.55% C: -3.01%
sage-718 disease treatment topline parkinson’s therapeutics results study

---

Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
Published: 2024-04-17 (Crawled : 01:00) - alteritytherapeutics.com
ATHE | $2.13 0.47% 31K |

Health Technology

| 3.9% | O: 0.0% H: 7.32% C: -1.95%
disease neurology system meeting parkinson’s therapeutics

---

argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
Published: 2024-04-16 (Crawled : 05:00) - globenewswire.com
ARGX | $375.08 1.72% 1.7% 1.3K |

Health Technology

| -1.12% | O: -5.0% H: 4.19% C: 2.86%
disease vyvgart for

---

Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
Published: 2024-04-15 (Crawled : 21:00) - globenewswire.com
ZVRA | $4.58 0.22% 0.44% 140K |

n/a

| -4.28% | O: 1.15% H: 1.03% C: -1.45%
disease treatment for meeting therapeutics

---

Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)
Published: 2024-04-15 (Crawled : 13:00) - globenewswire.com
LGVN 4 d | $1.82 -2.67% -4.47% 270K |

| 7.69% | O: 41.42% H: 42.68% C: 22.59%
conference disease association alzheimer’s presentation international research for trial

---

Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
OABI | News | $4.64 -0.86% -0.86% 370K |

| -8.12% | O: -1.58% H: 1.77% C: -0.4%
drug liver disease antibody for

---

Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
Published: 2024-04-11 (Crawled : 11:00) - globenewswire.com
IPSC | $3.13 2.62% 2.56% 75K |

Professional, Scientific, and T...

| -18.49% | O: 3.39% H: 11.53% C: 2.02%
disease million pipeline acquisition expansion therapeutics

---

Biomica to Present at Digestive Disease Week (DDW) Conference 2024 Annual Meeting
Published: 2024-04-11 (Crawled : 11:00) - prnewswire.com
EVGN | $0.7 -13.64% 63K |

Health Technology

| -0.87% | O: -0.87% H: 0.0% C: 0.0%
conference disease meeting week

---

Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
Published: 2024-04-11 (Crawled : 11:00) - globenewswire.com
ATHA | $2.04 -2.39% -2.7% 100 |

Health Technology

| -16.73% | O: 4.9% H: 6.03% C: 3.11%
fosgonimeton pharma disease alzheimer’s publication treatment preclinical

---

Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
Published: 2024-04-11 (Crawled : 05:00) - globenewswire.com
LLY | News | $745.69 1.96% 0.04% 1.4M |

Health Technology

| -1.7% | O: 1.06% H: 0.47% C: -0.03%
fda device disease test granted blood designation for alzheimer's roche

---

Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
SILO | $1.78 -10.55% -10.56% 15K |

Finance and Insurance

| -16.82% | O: 1.87% H: 4.59% C: -3.67%
pharma disease alzheimer’s acquire spc-14

---

Gainers vs Losers

77%

23%

Top 10 Gainers

AGBA | $2.97 137.6% 54.87% 66M |

Finance

HKIT | $1.33 30.39% 27.14% 39K |

Technology Services

VRT 4 | $79.17 4.08% 19.36% 6.6M |

Electronic Technology

FOA 4 | $0.5144 -8.16% 15.43% 20 |

Finance and Insurance

EAST | $1.0835 16.17% 15.21% 100 |

Commercial Services

BOF | $1.17 6.36% 14.73% 15K |

TSLA | News | $144.68 1.85% 9.01% 93M |

Consumer Durables

BNED | $0.2064 2.64% 8.96% 1.4M |

Retail Trade

HLTH | $0.15 6.38% 7.84% 21K |

LRN 4 | $58.2 0.17% 7.56% 950K |

Consumer Services

---

Your saved searches

---